SCHOTT will showcase its full line of packaging innovations at Interphex booth 3621, including adaptiQ® ready to use pharma vials and new ISO sizes of SCHOTT Vials DC (Delamination Controlled). For the first time, the company will also be presenting a polymer prefillable syringe for sensitive drugs the new SCHOTT TopPac® SD. The Interphex 2015 trade show will take place April 21-23 at the Javits Center in New York City.
SCHOTT Vials DC bring the advantages of reduced delamination propensity and decreased risk of product recalls to the pharma industry. They are made with high-quality FIOLAX® glass tubing and undergo an optimized hot forming process. Each product batch is subjected to a testing routine in the course of production that checks for delamination risks. At Interphex, SCHOTT shows the expanded portfolio of Vials DC, which now includes 2R, 4R, 6R and 8R ISO formats, with 10R to follow soon.
Ready-to-use vials: A new generation of possibilities
Designed in close collaboration with filling-line manufacturers to meet the industry’s process requirements, adaptiQ® consists of a patented nest that securely holds up to 100 clean and sterile vials in an industry-standard tub. Users can load these directly onto their filling lines without having to perform arduous processing steps, such as washing, drying, and sterilizing. Besides simplifying the process, the new nested packaging protects the glass containers from scratches caused by vial-to-vial and vial-to-machine contact. This reduces the reject rate and also preserves the cosmetic quality of the vials. SCHOTT’s adaptiQ® vials will be available from the company’s US production site in Lebanon, Pennsylvania, for purchase early in 2015 (2R and 4R ISO formats). SCHOTT will gradually introduce adaptiQ® in all common ISO formats, from 2R to 30R. Samples are now available for evaluation.
New Polymer Prefillable Syringe for Sensitive Drugs
As pharma companies are looking for faster time to market for sensitive drugs, SCHOTT’s TopPac SD polymer prefilled syringe incorporates new features for a reduced E&L (extractables and leachables) profile. Through specific component selection and an optimized processing method, SCHOTT TopPac® SD offers a significantly reduced level of impurities, decreasing the chance of drug/container interaction. The syringe features an inert COC barrel (cyclic olefin copolymer) that releases no ions or heavy metals, and reduces the chances of a chemical interaction with sensitive drugs. Additionally, the syringe was developed with pure elastomer components in order to reduce the E&L profile. Cross-linked silicone for barrel lubrication reduces the amount of subvisible particles with optimal functionality. Finally, the new syringes are sterilized with an ETO (Ethylene Oxide) sterilization method, rather than irradiation, to further reduce the E&L profile.
adaptiQ® and SCHOTT TopPac® are registered trademarks of SCHOTT AG and SCHOTT North America, Inc.
SCHOTT (schott.com) is a leading international technology group in the areas of specialty glass and glass-ceramics. The company has more than 130 years of outstanding development, materials, and technology expertise and offers a broad portfolio of high-quality products and intelligent solutions. SCHOTT is an innovative enabler for many industries, including the home appliance, pharmaceutical, electronics, optics, automotive, and aviation industries. SCHOTT strives to play an important part of everyone’s life and is committed to innovation and sustainable success. The group maintains a global presence with production sites and sales offices in 35 countries. With its workforce of approximately 15,400 employees, sales of $2.55 billion were generated in fiscal year 2013/2014.
Press contact: Mike Lizun - Gregory FCA on behalf of SCHOTT